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Abstract
Background: To evaluate the feasibility and value of first-pass contrast-enhanced dynamic and post-contrast 3D
CMR in patients after transcatheter occlusion of left atrial appendage (LAA) to identify incorrect placement and
persistent leaks.
Methods: 7 patients with different occluder systems (n = 4 PLAATO; n = 2 Watchman; n = 1 ACP) underwent 2
contrast-enhanced (Gd-DOTA) CMR sequences (2D TrueFISP first-pass perfusion and 3D-TurboFLASH) to assess
localization, artifact size and potential leaks of the devices. Perfusion CMR was analyzed visually and semi-
quantitatively to identify potential leaks.
Results: All occluders were positioned within the LAA. The ACP occluder presented the most extensive artifact
size. Visual assessment revealed a residual perfusion of the LAA apex in 4 cases using first-pass perfusion and 3D-
TurboFLASH indicating a suboptimal LAA occlusion.
By assessing signal-to-time-curves the cases with a visually detected leak showed a 9-fold higher signal-peak in the
LAA apex (567 ± 120% increase from baseline signal) than those without a leak (61 ± 22%; p < 0.03). In contrast,
the signal increase in LAA proximal to the occluder showed no difference (leak 481 ± 201% vs. no leak 478 ±
125%; p = 0.48).
Conclusion: This CMR pilot study provides valuable non-invasive information in patients after transcatheter
occlusion of the LAA to identify correct placement and potential leaks. We recommend incorporating CMR in
future clinical studies to evaluate new device types.
Background
Atrial fibrillation is the most common sustained cardiac
arrhythmia and affects 5 percent of people older than 65
years and 10 percent older than 75 years [1]. It repre-
sents a major risk factor for ischemic cerebral stroke or
peripheral embolism, especially due to embolism of
thrombi forming in the left atrial appendage (LAA).
LAA is the main location for left atrial thrombus forma-
tion related to the phenomenon of atrial stunning [2].
Anticoagulation is required to prevent further cerebral
events as patients in atrial fibrillation have a 5-fold
higher risk of embolic stroke than those in sinus rhythm
[3-5].
However, long-term anticoagulation is frequently asso-
ciated with problems of safety and tolerability, such as
increased risk of bleeding. Occlusion of the left atrial
appendage could be a potential alternative strategy for
prophylaxis of embolism. In comparison to surgical
amputation, the percutaneous transcatheter occlusion of
LAA is a minimally invasive technique and yields pro-
mising results in animal [6] and human studies [7-13].
Currently, following the transcatheter procedure, a
chest X-ray is performed to confirm the correct place-
ment of the occluder and transesophageal echocardio-
graphy allows for the evaluation of possible thrombotic
appositions on the device. To date, it has been still chal-
lenging to assess directly and non-invasively the residual
LAA perfusion indicating a persistent leak due to an
insufficient design, a mismatch of device and LAA anat-
omy or a failure of complete coverage of the atrial-
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cells [7]. A persistent leak detected by CMR may be
important as this could indicate a remaining risk of
thromboembolism from the LAA.
The purpose of this pilot study was to evaluate the
feasibility and value of first-pass contrast-enhanced
dynamic and post-contrast 3D CMR in patients after
transcatheter occlusion of LAA to identify incorrect pla-
cement and persistent leaks.
Materials and methods
Study Population
7 adult patients (mean age 68 ± 8, range 56-78 years; 2
females and 5 males) with non-rheumatic atrial fibrilla-
tion received transcatheter occlusion of LAA due to
warfarin contraindications (intracerebral bleeding, thom-
boembolic events despite warfarin therapy, exanthema).
4 patients received a PLAATO device (eV3 Inc., Min-
neapolis, MN, USA), 2 patients a Watchman device
(Atritech Inc.; Minneapolis; MN, USA) and one patient
an ACP device (AGA Medical Inc., Plymouth, MN,
USA). Our study population for this pilot study was
drawn from subsequent patients undergoing transcath-
eter occlusion of LAA with clinically suspected device
malposition or residual leaks who consented to partake
in this CMR study. The different designs of the devices
are displayed in Figure 1.
The patients underwent CMR median 102 days (range
91-229 days) after the LAA occlusion procedure after
written informed consent had been obtained. None of
the patients had suffered a stroke between the
transcatheter occlusion of LAA and the date of the
CMR scans. The study was approved by the local ethics
committee.
Magnetic Resonance Imaging
Magnetic resonance imaging was performed on a 1.5-T
CMR system (MAGNETOM Avanto with SQ-engine
gradients, Siemens AG, Healthcare Sector, Germany).
For signal detection, the combinations of a six-channel
body matrix coil and six elements of a spine matrix coil
were used. The ECG-signal was received via an external
system (Magnitude 3150, InVivo Research Inc., Orlando,
FL, USA).
ECG-gated segmented steady-state-free-precession
(SSFP) cine-sequences (TR = 2.7 ms, TE = 1.2 ms, tem-
poral resolution 34 ms, voxel-size = 1.7 × 1.3 × 6.0
mm
3) served to determine LAA anatomy and for detec-
tion of the occluder system.
Two slices of a saturation-recovery SSFP sequence
(TrueFISP, TE = 2.7 ms, TI = 217 ms, flip angle 50°,
temporal resolution 832 ms, matrix 144 × 256, voxel-
s i z e=1 . 8×1 . 4×6 . 5m m
3) were performed simulta-
neously planned from the optimal views on cine studies
in the oblique axial and sagittal long axis. For each slice
40 consecutive images were acquired during the admin-
istration of a bolus of Gadoterate Meglumin (0.1 mmol/
kg bodyweight Gd-DOTA, Dotarem, Guerbert) followed
by 30 ml saline, both at 4 ml/second into an antecubital
vein.
After the administration of another 0.1 mmol/kg
bodyweight Gd-DOTA (Dotarem, Guerbet) an ECG-
gated 3D-TurboFLASH sequence (TE = 1.5 ms, TI was
optimized [typical values 200-350 ms], minimum acqui-
sition window typically 451 ms, flip angle 10°, matrix
152 × 256, number of slices = 12, voxel size = 1.9 × 1.4
× 4.0 mm
3) was acquired in the same optimized planes.
Image analysis
The data sets (cine localizer sequences, dynamic first
pass perfusion and post-contrast 3D images) were evalu-
ated by consensus of 2 observers experienced in cardio-
vascular radiology. The readings were performed
blinded to any clinical information. In every patient the
readers evaluated qualitatively for occluder size (includ-
ing surrounding metal-related, artificial signal void),
occluder localization (judged as either outside LAA, at
the LAA ostium or deep into the LAA body) and persis-
tent leaks (contrast enhancement of the LAA apex distal
to the occluder device).
Additionally, contrast-enhanced perfusion studies were
analyzed generating signal-time-curves (using Syngo
“mean curve"; Siemens AG healthcare, Germany). Two
different regions of interest (ROIs) were placed in the
left atrium and in the LAA apex distal to the occluder
Figure 1 Different LAA occluder device types. Common criteria
are transcatheter transseptal delivery via femoral venous access, self-
expanding nitinol-made cage or mesh, designed to be permanently
implanted at or slightly distal to the LAA ostium to trap potential
emboli before they exit the LAA. A (left panel) shows the
historically first LAA device named PLAATO (Appriva Medical Inc.)
with a nitinol-made cage covered with an polytetrafluoroethylene
membrane with small anchors along the struts; range of diameters
15-32 mm. Faced to the apex of left atrial appendage the cover is
opened for the filling of blood and a later thrombosis inside the
device. B (middle panel) shows the Watchmen device (Atritech
Inc.) with a polyethylene membrane on the atrial-faced surface of a
nitinol-made cage and a row of fixation barbs; range of diameters
21-33 mm. C (right panel) ACP device (AGA Medical Inc.) is
constructed from a nitinol mesh and polyester patch, consists of a
lobe and a disc connected by a central waist; range of diameters
16-30 mm.
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fitted to every image without changing the size. The sig-
nal-time-curves were normalized to baseline signal (sec-
ond image, as the signal in the first image was not fully
saturated after the saturation-preparation pulse) for each
ROI [14]. The single data points represent the percen-
tage signal increase compared to the baseline signal.
Statistical Analysis
Statistical analysis was performed using SPSS 18.0.
Quantitative data are presented as mean and standard
deviation or median and range when appropriate. The
independent samples Mann Whitney U Test (non-para-
metric test) was performed to assess for differences in
time to the signal peaks in the left atrium and the LAA
apex and signal peaks as a percentage to baseline signal.
A p value less than 0.05 was considered statistically
significant.
Results
Sizes and localization of occluder devices
There was no dislocation of the devices outside the
LAA. In 4 cases the atrial-facing device border was loca-
lized at the ostium of LAA whereas in 3 cases the device
was localized more deeply within the LAA body. All of
the 3 cases with device localization more deeply within
the LAA presented a leak but only one localized at the
ostium of LAA. In 5 cases the occluder-related signal
voids show a slight bulging (4.2 ± 3.6 mm) into the left
atrium. The mean size of the occluder device including
surrounding artefacts was 28.6 × 25.3 × 25.4 ± 3.9 × 3.3
× 3.1 mm.
Baseline characteristics of each patient are presented
in table 1. Figure 2 illustrates the different types and
CMR-related aspects of devices.
Assessment of residual leaks
Visual evaluation of contrast-enhanced first-pass perfu-
sion CMR revealed contrast enhancement at the apex of
the LAA beyond the device indicating a residual leak in
4 cases.
Patients with visually detected residual perfusion
showed 9-fold higher peaks in the LAA apex distal to
the device (567 ± 120% from baseline signal) than those
without a leak (61 ± 22% from baseline signal; p < 0.03).
In contrast, the signal peaks in the left atrium body
showed no difference in patients with compared to
patients without leaks (leak 481 ± 201% vs. no leak 478
± 125%; p = 0.48).
The time to signal peaks was similar in patients with
and without leaks in the left atrium (leak 26 ± 6 heart-
beats vs. no leak 20 ± 3 heartbeats; p = 0.16) or in the
LAA (leak 21 ± 10 heartbeats vs. no leak 28 ± 5 heart-
beats; p = 0.47).
According to the anatomical size the median pixel size
of ROIs in the left atrium (58 pixel; range 37-221 pixel)
was larger than in the left atrial appendage (21 pixel;
range 12-34 pixel).
Cases of visually detected residual leaks after transcath-
eter LAA occlusion are presented in Figure 3 and 4.
Please also see movies 1 and 2 (additional file 1 and 2)
which show the temporal sequence of first-pass contrast-
enhanced perfusion imaging. Figure 5 and 6 compare sig-
nal-to-time curves in patients without and with a residual
perfusion of the LA (Figure 5) and LAA (Figure 6).
Discussion
Our pilot study highlights the potential role of contrast
enhanced CMR to evaluate the localization of LAA
occluder systems and to detect residual leaks after
implantation.
Table 1 Baseline characteristics
No. Device
type
Real
device
diameter
[mm]
CMR
device
signal
void [mm]
CMR
device
localization
Residual
leak
Time to left
atrial signal
peak
[heartbeats]
Left atrial
signal peak
[% from
baseline]
Time to left atrial
appendage signal
peak [heartbeats]
Left atrial
appendage signal
peak [% from
baseline]
1 PLAATO 26 30 × 24 ×
24
LAA body Yes 22 582 29 519
2 PLAATO 29 31 × 27 ×
27
LAA body Yes 18 550 24 502
3 PLAATO 32 31 × 29 ×
29
LAA ostium No 32 249 10 39
4 PLAATO 29 31 × 27 ×
27
LAA body Yes 16 302 25 746
5 ACP 22 31 × 28 ×
28
LAA ostium No 20 602 25 83
6 Watchman 22 22 × 21 ×
21
LAA ostium No 26 592 29 61
7 Watchman 27 24 × 21 ×
22
LAA ostium Yes 23 476 35 499
Mohrs et al. Journal of Cardiovascular Magnetic Resonance 2011, 13:33
http://www.jcmr-online.com/content/13/1/33
Page 3 of 7Atrial fibrillation affects 3-5% in patients older than 65
years and is responsible for 15-20% of strokes [15]. Due
to the risk of thromboembolism many patients with
atrial fibrillation are treated with anticoagulants. But
long-term therapy with warfarin is associated with an
increased risk of minor (5 to 10% per year) and major
(1-2% per year) hemorrhagic complications [16]. This
underlies the rationale to establish alternative
approaches, such as transcatheter percutaneous LAA
occlusion. Research study protocols define successful
treatment as correct placement of the device at or
slightly distal to the LAA ostium, appropriate implant
size by measuring the deployed diameter of the implant
in situ and the absence of residual LAA perfusion.
Currently, chest X-ray and echocardiography are used
after transcatheter procedure to verify correct placement
of the device and to exclude thrombotic appositions or
residual leaks. But chest X-ray is only able to detect
extracardiac displacement and echocardiography is lim-
ited to evaluate residual flow since flow velocities within
LAA in patients with atrial fibrillation are highly variable
even before the procedure [17]. Pre-procedural measure-
ments of LAA by transesophageal echocardiography do
not always accurately predict the size of LAA occlusion
devices and it is still unclear how accurately transeso-
phageal echocardiography is able to confirm the correct
placement of the device during and after the procedure
[18]. Also, the major drawback of transesophageal
echocardiography is its semi-invasiveness and the need
for sedation in many cases.
There are age- and sex-related differences in LAA
dimensions as well as various anatomical variants
[19,20]. Accurate measurement of LAA diameters is
very challenging and probably high-resolution contrast-
enhanced cardiac CT will play a major role prior to
transcatheter procedures in the future [18]. However,
CMR offers non-invasively and without any radiation a
reliable evaluation of post-procedural localization and
potential residual leaks of the device as documented in
our study. Currently, for safety concerns a time interval
of 6 weeks between implantation and CMR examination
is recommended for intracardiac devices to ensure that
the device is fixed to the endocardial tissue [21]. In gen-
eral, LAA occluder devices are safe, especially nitinol-
based intracardiac devices [22].
Over- or undersizing, device migration or displace-
ment could contribute to unsuccessful device deploy-
ment. Incomplete occlusion of LAA is one of the major
concerns leaving the clinician in the dilemma of whether
it is safe to stop warfarin therapy. CMR-based measure-
ments could be helpful to understand the principle of
residual leaks due to potential for suboptimal device
deployment. All devices with residual perfusion were
localized deeper into the LAA and a small rim of con-
trast agent could be identified around the margins of
the device using 3D imaging sequences.
Figure 2 Different appearance of LAA devices. Cine TrueFISP-SSFP sequences demonstrate signal voids within LAA representing the correct
placement and the exclusion of a migration of the devices: 1A (left panel) PLAATO device; 1B Watchmen device and 1C ACP device. For
comparison figure 1D (right panel) shows a chest-X-ray of a PLAATO device.
Figure 3 67-year-old male after percutaneous transcatheter LAA occlusion using a Watchman device. Figures 3A-D show the temporal
sequence of first-pass contrast-enhanced perfusion imaging (see also movie 1 and 2). A (left): contrast-enhancement of the pulmonary trunk
(arrow) but not in the left atrium (dotted arrow); typical signal loss at the framework of the device (circle). B (middle): contrast-enhancement in
left atrium (dotted arrow) but not inside the device or at the apex of left atrial appendage (circle). C (right): contrast-enhancement of the LAA
apex beyond the device representing a slow wash-in due to a small residual leak.
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able using qualitative visual assessment, which obviates
the need for time-consuming post-processing. However,
less experienced observers may wish to confirm the
visual assessment by semi-quantitative assessment and
we identified 9-fold higher signal intensity peaks. A pos-
sible underlying problem of using our proposed CMR
perfusion technique needs to be considered in the con-
text of devices causing metal artifacts which can lead to
spurious local increase of signal in the LAA region
before contrast arrival and/or possible loss of contrast
related signal after its arrival in the test region.
Limitations
The high incidence of residual leaks after transcatheter
LAA occlusion in our pilot study result is due to a selec-
tion bias as we only included patients in whom problems
of device malposition or residual leaks were suspected and
does not contradict the very promising results of this ther-
apy approach [7-13]. However, this study was designed to
Figure 4 Comparison of a post-Gadolinium 3D TurboFLASH sequence in patients with an insufficient coverage of the LAA after
transcatheter LAA occlusion using a Watchmen device (4A left) and a PLAATO device (4B right). Note the enhancement around the
margins (arrows) and of the LAA apex beyond the device (dotted arrows) indicating a residual leak.
Figure 5 Comparison of normalized signal-time curves of all 7 patients in the left atrium. As expected, LA signal-time curves show a
similar pattern of enhancement in patients without (blue dashed lines with diamond symbols) and with (red solid lines with dot symbols)
sufficient coverage (i.e. with leak) of the transcatheter occlusion of the LAA.
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occluder dislocation and residual LAA perfusion.
Residual perfusion could be a source of thromboem-
boli and these patients might be considered for further
anticoagulation. However, despite our encouraging
initial experience using contrast-enhanced CMR, this
warrants further investigation regarding its predictive
value and impact on treatment strategies. Given the
small numbers of LAA device occlusion performed even
in specialist centres, this should be done in a multi-cen-
ter study.
Our pilot study did not address the important ques-
tion whether CMR is able to detect small thrombi on
the device surface. In this pilot study we did not com-
pare our findings to transoesophageal echocardiography.
Determination of signal time curves without partial
volume effect can be difficult or occasionally impossible
to obtain due to the complex and variable left atrial
appendage anatomy. However, leaks around the left atrial
appendage occluder device are usually visible and the sig-
nal time curves are most often for confirmation only.
Conclusions
CMR is feasible to confirm occluder placement and to
detect residual LAA leaks non-invasively and without
radiation. Given the variable and complex anatomy of
the LAA CMR may inform device companies how to
tailor and optimize the design of such devices and to
test them in small pilot studies. We propose that clinical
trials to test LAA occlude devices should incorporate
contrast-enhanced CMR.
Additional material
Additional file 1: Movie of a residual peak in sagital angulation. 67-
year-old male after percutaneous transcatheter LAA occlusion using a
Watchman device. The movie shows the temporal sequence of first-pass
contrast-enhanced perfusion imaging in sagital angulation. The contrast-
enhancement of the LAA apex beyond the device is representing a slow
wash-in due to a small residual leak.
Additional file 2: Movie of a residual peak in axial angulation. Same
patient and findings as in additional file 1 (movie 1) but in an axial
angulation.
Figure 6 Comparison of normalized signal-time curves of all 7 patients in the left atrial appendage. LAA signal-time curves behave in
two patterns: No discernible peaks can be seen in normalized signal-time curves in patients with sufficient LAA occlusion and peaks of at least
200% compared to normalized baseline can be seen in those without sufficient coverage of the transcatheter occlusion of the LAA. All signal-
time curves start with the second heartbeat which was used for normalization of the signal-time curves (the first image was not used due to
incomplete saturation). Variations in the erratic signal-time curve (green solid line with dot symbols) likely represents partial volume effects due
to suboptimal breath holding or arrhythmia (atrial fibrillation). The solid curve in the right panel with two positive peaks in the early part of the
signal time curve are likely due to such a partial volume effect, as the maximal possible region of interest which could be drawn consisted of
only 12 pixels. The differences in magnitude of the peak signal could be caused by individual contrast geometry variations.”
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LAA: left atrial appendage; CMR: cardiac magnetic resonance imaging; Gd-
DOTA: gadolinium gadoterate meglumin; 3D: three-dimensional; FLASH: fast-
low-angle-shot; FISP: Fast Imaging with Steady State Precession; SSFP:
steady-state-with-free-precession; ROI: region of interest; CT: computed
tomography.
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